United Therapeutics

At a glance

United Therapeutics reported 2025 revenue of $3.18B, up 10.6% from $2.88B in 2024. Over 4 years since 2021 ($1.69B), that is growth of about 17.2% a year. Operating margin was 46.9%, up from 33% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 12 insiders reported 1 open-market purchase ($864K) and 292 sales ($1.45B). 283 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $14.3M by PRESIDENT AND COO Michael Benkowitz on Jan 28, 2026. Net, insiders were sellers of $1.45B.

United Therapeutics filed 12 current reports (Form 8-K) in the last 12 months, most often for other events (3), results of operations (3), officer or director change (3) and material agreement (2). The latest officer or director change was reported on Jul 23, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

3 of the 20 investors tracked here held United Therapeutics at the last quarter end, worth $1B combined. It is the largest weight for Renaissance Technologies (1.3% of its portfolio), followed by Bridgewater Associates (0.2%). Reduced: Renaissance Technologies and National Pension Service (Korea).

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.